Denileukin diftitox
Also known as: DAB389IL-2, Denileukin diftitox, E7777, IL-2 diphtheria toxin fusion protein, Lymphir, Ontak
Source Denileukin diftitox at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Denileukin diftitox is a recombinant fusion protein that couples fragments of diphtheria toxin to human interleukin‑2. It is approved for intravenous use in patients with relapsed or refractory cutaneous T‑cell lymphoma (CTCL) and has been investigated in other IL‑2‑receptor‑positive hematologic cancers. By targeting cells that express the high‑ or intermediate‑affinity IL‑2 receptor, it delivers a cytotoxic payload that halts protein synthesis and induces rapid cell death.
Mechanism of Action
The IL‑2 component of denileukin diftitox binds to the α (CD25) and/or βγ (CD122/CD132) subunits of the high‑ or intermediate‑affinity IL‑2 receptor on activated lymphocytes and some malignant cells. The complex is internalized into endosomes, where proteolytic cleavage releases the diphtheria toxin fragment A. This fragment ADP‑ribosylates elongation factor‑2, blocking protein synthesis and triggering apoptosis of the receptor‑bearing cell.
What the Research Shows
Early clinical experience described the drug’s ability to bind IL‑2R‑positive lymphoma cells and cause rapid cytolysis (Foss 2006). A 2000 trial reported overall response rates of 23‑36% at 9‑18 µg/kg/day for five days every three weeks, with quality‑of‑life gains in responders and common toxicities such as hypoalbuminemia and vascular leak. A large phase III open‑label study of an improved‑purity formulation (DD‑cxdl) in 69 relapsed/refractory CTCL patients showed a 36.2% objective response rate, including 8.7% complete responses, median duration of response of 8.9 months, and reductions in skin tumor burden in 84% of participants. The drug is listed among approved cancer immunotherapies, highlighting its role as an immunotoxin, though most data focus on CTCL.
Reported Benefits
Clinical trials demonstrate that denileukin diftitox can achieve objective responses in about one‑third of patients with relapsed/refractory CTCL, with complete responses in a minority. Responders often experience meaningful reductions in skin lesions and improved quality of life. The improved‑purity formulation appears to maintain efficacy while delivering a manageable safety profile, addressing an unmet need for patients who have failed other systemic therapies.
Limitations of the Evidence
Evidence is largely confined to CTCL; data for other leukemias or lymphomas are limited and mostly pre‑clinical. The pivotal phase III trial was single‑arm and open‑label, lacking a comparator group. Long‑term survival benefits remain uncertain, and the development of neutralizing antibodies may affect durability of response. Real‑world effectiveness outside trial settings has not been extensively reported.
Safety Considerations
The most frequent adverse events are infusion‑related reactions, hypersensitivity, nausea, fatigue, and hepatotoxicity. Capillary or vascular leak syndrome occurs in about one‑fifth of patients, with severe cases in roughly 5‑6%. Hypoalbuminemia, fever, and asthenia are also reported. Antibody formation is common but does not necessarily abolish clinical benefit. Caution is advised in patients with hepatic impairment or a history of severe vascular leak.
How It Is Administered
Denileukin diftitox is administered intravenously as a daily infusion for five consecutive days, repeated every 21 days for up to eight cycles. Dosing is expressed in micrograms per kilogram of body weight. The formulation used in recent studies (DD‑cxdl) is an improved‑purity version of the original product.
Routes of Administration
Goals & Uses
- Treatment of CD25+ cutaneous T-cell lymphoma (CTCL)OncologyHigh
- Treatment of peripheral T-cell lymphoma (PTCL)OncologyModerate
- Cutaneous T‑cell lymphoma (CTCL)OncologyHigh
- Immunosuppression in graft-versus-host diseaseImmunologyLow
- Peripheral T‑cell lymphomaOncologyModerate
Contraindications
- Hypersensitivity to diphtheria toxin or IL-2Allergy/ImmunologyHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- Severe infection or sepsisInfectionModerate
- Active uncontrolled infectionInfectious DiseaseModerate
- Known hypersensitivity to denileukin diftitox or diphtheria toxinAllergyHigh
Adverse Effects
- HepatotoxicityHepaticCommonLiver injury or dysfunction
- Capillary leak syndromeVascularRareLeakage of fluid from blood vessels into tissues
- HypoalbuminemiaMetabolicCommon
- Nausea/vomiting/fatigueGastrointestinal/GeneralCommon
- Hepatotoxicity (elevated transaminases)HepaticUncommon
- Visual loss / decreased visual acuityOphthalmologicUncommon
- Infusion-related reactionsHypersensitivityCommon
- Infusion‑related reactions (fever, chills, nausea)GeneralCommon
Drug Interactions
- Live vaccinesHigh
- CyclosporineModerate
- Nephrotoxic agentsModerate
- CorticosteroidsModerate
- ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
Population Constraints
- Pediatric patientsAgeRelative
- Breastfeeding womenReproductiveRelative
- Patients with serum albumin <3 g/dLLaboratoryRelative
- Pediatric patients (<12 years)PediatricRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedNever received marketing authorization in the European Union.
- United StatesWithdrawnApproved: Cutaneous T‑cell lymphoma (relapsed/refractory)Product withdrawn from market in 2008; no current FDA approval.
- United KingdomUnknownNot approved by MHRA as of 2024.
Withdrawn from US market due to manufacturing and supply issues; no current FDA approval. A next‑generation analogue (E7777) remains investigational.
Evidence & Sources
- Journal ArticleModerateFoss F2006-01-01T00:00:00.000000Z
- Journal ArticleModerateFoss FM, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateFiggitt DP, Lamb HM, Goa KL2000-01-01T00:00:00.000000Z
- Journal ArticleModerateDillman RO2011-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of cancer is denileukin diftitox approved to treat?
It is approved for intravenous treatment of relapsed or refractory cutaneous T‑cell lymphoma, including mycosis fungoides and Sézary syndrome, after at least one prior systemic therapy.
How does denileukin diftitox target cancer cells while sparing normal tissue?
The drug binds specifically to the high‑ or intermediate‑affinity IL‑2 receptor, which is over‑expressed on activated lymphocytes and many T‑cell malignancies. Normal cells lacking these receptors are less likely to internalize the toxin.
What are the most common side effects patients should expect?
Patients frequently experience infusion‑related reactions, mild to moderate hypersensitivity, nausea, fatigue, and transient liver enzyme elevations. Vascular leak syndrome can occur and requires monitoring, especially during the first treatment cycles.
Is there a risk that the body will become resistant to the drug?
Most patients develop antibodies against the fusion protein, but studies have shown that antibody formation does not necessarily prevent a therapeutic response. Ongoing monitoring for loss of efficacy is recommended.
Can denileukin diftitox be combined with other cancer therapies?
Current approvals are for monotherapy in CTCL. While pre‑clinical data suggest potential synergy with other agents, clinical evidence for combination regimens is limited, and such use should be confined to clinical trials.
What is Denileukin diftitox?
Denileukin diftitox is a recombinant fusion protein that couples fragments of diphtheria toxin to human interleukin‑2. It is approved for intravenous use in patients with relapsed or refractory cutaneous T‑cell lymphoma (CTCL) and has been investigated in other IL‑2‑receptor‑positive hematologic cancers. By targeting cells that express the high‑ or intermediate‑affinity IL‑2 receptor, it delivers a cytotoxic payload that halts protein synthesis and induces rapid cell death.
What is Denileukin diftitox used for?
Denileukin diftitox is educationally associated with: Treatment of CD25+ cutaneous T-cell lymphoma (CTCL), Treatment of peripheral T-cell lymphoma (PTCL), Cutaneous T‑cell lymphoma (CTCL), Immunosuppression in graft-versus-host disease, Peripheral T‑cell lymphoma. Educational only — not medical advice.
How is Denileukin diftitox administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Denileukin diftitox?
Reported adverse effects include: Hepatotoxicity, Capillary leak syndrome, Hypoalbuminemia, Nausea/vomiting/fatigue, Hepatotoxicity (elevated transaminases), Visual loss / decreased visual acuity, Infusion-related reactions, Infusion‑related reactions (fever, chills, nausea). This list is not exhaustive — consult a qualified clinician.
Who should avoid Denileukin diftitox?
Recorded contraindications: Hypersensitivity to diphtheria toxin or IL-2, Severe hepatic impairment, Severe infection or sepsis, Active uncontrolled infection, Known hypersensitivity to denileukin diftitox or diphtheria toxin. Consult a qualified clinician before use.